Tradestie Institutional Equity Comparison Engine

IONS vs KRYS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KRYS Overall Edge

KRYS Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Krystal Biotech, Inc. Common Stock (KRYS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus KRYS at 33.1x Forward P/E and 48.4% operating margin (+30.2% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against KRYS sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner KRYS
IONS 90.9x vs KRYS 33.1x Fwd P/E
Growth & Margin Winner KRYS
Op Margin -58.8% vs 48.4% ยท YoY +54.9% vs +30.2%
Momentum & Technical Winner KRYS
1Y -59.1% vs +47.9% ยท 52W Pos 2% vs 54%
Options & Structure Winner KRYS
BREAKDOWN (17th %ile IV) vs CONSOLIDATION (4th %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
KRYS NASDAQ
Krystal Biotech, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$297.67
-2.48% 1D
Market Cap $9.1B
1M Return -5.97%
1Y Return +47.94%
Forward P/E 33.1x
Unified AI Score
51.1 / 100 HOLD
Tech 59.0 Fund 57.0 Flow 66.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% KRYS +47.94% Spread: +107.04 pp (KRYS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue KRYS Revenue IONS Op. Margin KRYS Op. Margin Margin Edge
FY2018 $600M N/A -10.2% N/A IONS
FY2019 $1.12B N/A 32.6% N/A IONS
FY2020 $730M N/A -23.6% N/A IONS
FY2021 $810M N/A -3.7% N/A IONS
FY2022 $590M N/A -69.8% N/A IONS
FY2023 $790M $50M -44.9% -216.2% IONS
FY2024 $710M $290M -67.4% 22.6% KRYS
FY2025 $940M $390M -40.4% 41.5% KRYS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (2) vs KRYS (8)
Institutional Metric IONS KRYS Criterion Row Winner
Market Capitalization Scale $4.7B $9.1B Larger Scale KRYS
Trailing P/E Ratio Valuation 90.9x 41.5x Lower Multiple KRYS
Forward P/E Ratio Valuation 90.9x 33.1x Lower Multiple KRYS
Revenue Growth (YoY) Growth +54.9% +30.2% Higher Growth IONS
Operating Margin (TTM) Profitability -58.8% 48.4% Higher Margin KRYS
Net Profit Margin Profitability -56.9% 47.9% Higher Margin KRYS
Return on Equity (ROE) Capital Efficiency -108.0% 17.5% Higher ROE KRYS
52-Week Range Position Momentum 2% ($27โ€“$87) 54% ($198โ€“$383) Stronger Trend KRYS
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 0.69ฮฒ ยท 47% Vol Lower Realized Risk KRYS
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 51.1 / 100 (HOLD) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs KRYS Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KRYS CONSOLIDATION
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live KRYS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor KRYS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.